Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was up 0.4% during trading on Tuesday . The company traded as high as $8.03 and last traded at $8.02. Approximately 580,307 shares traded hands during trading, a decline of 15% from the average daily volume of 683,086 shares. The stock had previously closed at $7.99.
Analyst Ratings Changes
Several equities research analysts recently weighed in on VIGL shares. Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright cut shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and dropped their price target for the company from $14.00 to $8.00 in a research note on Tuesday, May 27th. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the company a "neutral" rating in a research note on Thursday, May 22nd. Stifel Nicolaus cut shares of Vigil Neuroscience from a "buy" rating to a "hold" rating and lowered their target price for the company from $11.00 to $8.00 in a report on Wednesday, May 28th. Finally, Citigroup downgraded Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $10.80.
Get Our Latest Stock Analysis on VIGL
Vigil Neuroscience Stock Performance
The stock has a market capitalization of $384.12 million, a PE ratio of -3.93 and a beta of 3.34. The business's 50-day moving average price is $6.40 and its 200 day moving average price is $3.55.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, equities research analysts predict that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.
Hedge Funds Weigh In On Vigil Neuroscience
A number of hedge funds and other institutional investors have recently bought and sold shares of VIGL. BVF Inc. IL lifted its holdings in shares of Vigil Neuroscience by 121.3% during the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock worth $7,144,000 after acquiring an additional 2,200,000 shares during the last quarter. 683 Capital Management LLC raised its position in Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock valued at $3,097,000 after purchasing an additional 340,000 shares in the last quarter. Aberdeen Group plc lifted its stake in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock worth $3,070,000 after purchasing an additional 1,196,048 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Vigil Neuroscience by 219.1% in the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after purchasing an additional 709,677 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its position in shares of Vigil Neuroscience by 16.1% during the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock valued at $1,195,000 after purchasing an additional 97,580 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.
Vigil Neuroscience Company Profile
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
See Also
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
